成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Duteplase

Duteplase Struktur
120608-46-0
CAS-Nr.
120608-46-0
Englisch Name:
Duteplase
Synonyma:
Duteplasa;Duteplase;Duteplasum;Duteplasum [inn-latin];Duteplasa [inn-spanish];Plasminogen activator (human tissue-type 2-chain form protein moiety), 245-L-methionine-
CBNumber:
CB51117405
Summenformel:
C2HNOS46
Molgewicht:
0
MOL-Datei:
Mol file

Duteplase Eigenschaften

Sicherheit

Duteplase Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Duteplase, a nearly pure double-chain recombinant tissue-type plasminogen activator (rt-PA), was introduced in Japan for the treatment of acute myocardial infarction. Similar to other thrombolytic agents, duteplase acts by converting the proenzyme plasminogen to the active enzyme plasmin, resulting in fibrinolysis and varying degrees of depletion of circulating fibrinogen, factor V and factor VIII. In patients with acute myocardial infarction, treatment with duteplase induced patency rate of infarct-related artery at 90 minutes by up to 69%. Compared with alteplase, a single-chain rt-PA, duteplase has similar activity but a slower clearance rate and thus lower doses of duteplase have a similar therapeutic effect to alteplase.

Originator

SumItomo (Japan)

Trademarks

Solclot

Duteplase Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Duteplase Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 4)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Leancare Ltd. --
enquiry@leancare.co.uk United Kingdom 6446 42
Lanospharma Laboratories Co.,Ltd --
sales@lanospharma.com China 6329 56
2A PharmaChem USA --
sales@2apharmachem.com United States 6137 39
3B Scientific Corporation --
sales@3bsc.com United States 6718 47

  • Duteplase
  • Duteplasa
  • Duteplasa [inn-spanish]
  • Duteplasum
  • Duteplasum [inn-latin]
  • Plasminogen activator (human tissue-type 2-chain form protein moiety), 245-L-methionine-
  • 120608-46-0
  • C2HNOS46
Copyright 2019 ? ChemicalBook. All rights reserved